A Study of LY3945262 in Healthy Participants
A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY3945262 and an Open Label, Randomized, Fixed Sequence, Relative Bioavailability Study of LY3945262 in Healthy Participants
The main purpose of this study is to evaluate how well LY3945262 is tolerated, what side effects may occur, and how much LY3945262 gets into the bloodstream and how long it takes the body to remove it in healthy participants. The study will also compare how LY3945262 gets into the bloodstream when administered in different ways.
This study will last approximately 8 weeks and may include up to 4 visits.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 电话号码:1-317-615-4559
- 邮箱:LillyTrials@Lilly.com
研究联系人备份
- 姓名:Physicians interested in becoming principal investigators please contact
- 邮箱:clinical_inquiry_hub@lilly.com
学习地点
-
-
California
-
Los Alamitos、California、美国、90720
- Collaborative Neuroscience Network - CNS
-
首席研究员:
- Steven Reynolds
-
接触:
- 电话号码:844-424-9494
-
-
Texas
-
San Antonio、Texas、美国、78232
- ICON Early Phase Services
-
接触:
- 电话号码:210-283-4500
-
首席研究员:
- Chinonye Ogbonnaya-Odor
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and electrocardiogram (ECG).
- To qualify as Japanese for the purpose of this study, the participant must be first generation Japanese, defined as the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent, and must have been born in Japan.
- To qualify as Chinese for the purpose of this study, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participant's biological grandparents must be of exclusive Chinese descent, and must have been born in China.
-
Individuals assigned male at birth (AMAB) and individuals not of childbearing potential (INOCBP) may participate in this trial. Individuals of childbearing potential (IOCBP) are excluded from this trial.
-
Have a body weight of at least 50 kilogram (kg) and body mass index within the range of 18.5 to less than or equal to 35 kilogram per square meter (kg/m²).
Exclusion Criteria:
-
Have a significant history, or current evidence, of any of the following types of disorders that could significantly alter the absorption, metabolism, or elimination of drugs; pose a risk during administration of the investigational product; or interfere with data interpretation:
- cardiovascular
- respiratory, including bronchospasm or bronchial asthma, or chronic obstructive airways disease
- hepatic
- renal
- gastrointestinal
- endocrine, such as diabetes, acromegaly, Cushing syndrome, hyper- or hypothyroidism (Including subclinical hypothyroidism measured using thyroid stimulating hormone), or hyperaldosteronism
- hematological
-
Have a history of hypertension, or a blood pressure (BP) reading that is abnormal for the population
-
Have known or ongoing psychiatric disorders.
-
Have used or intend to use over the counter or herbal supplements (for example, St. John's wort) or prescription medication within 14 days or 5 half-lives, whichever is longer, before initial dosing or during the study. If this situation arises, inclusion of an otherwise suitable participant may be at the discretion of the investigator and sponsor.
-
Regularly use known drugs of abuse and/or show positive findings on drug screening.
-
Are currently enrolled in any other clinical trial involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.
-
Have participated, within the past 30 days, in a clinical study involving an investigational product with a short half-life. If the previous investigational product has a long half-life, 3 months or 5 half-lives, whichever is longer, should have passed.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LY3945262 Part A (SAD)
Single Ascending Doses (SAD) of LY3945262 administered orally |
Administered Orally |
|
安慰剂比较:Placebo Part A (SAD)
Placebo administered orally |
Administered Orally |
|
实验性的:LY3945262 Part B (MAD)
Multiple Ascending Doses (MAD) of LY3945262 administered orally. Participants will also receive 2 doses of Midazolam (one before and one with LY3945262) administered orally. |
Administered Orally Administered orally |
|
安慰剂比较:Placebo Part B (MAD)
Placebo administered orally. Participants will also receive 2 doses of Midazolam (one before and one with placebo) administered orally. |
Administered Orally Administered orally |
|
实验性的:LY3945262 Part C (Test)
LY3945262 tablet formulation administered orally |
Administered Orally |
|
有源比较器:LY3945262 Part C (Reference)
LY3945262 capsule formulation administered orally |
Administered Orally |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
大体时间:Baseline to Study Completion (Up to 8 weeks)
|
Baseline to Study Completion (Up to 8 weeks)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3945262
大体时间:Baseline to Study Completion (Up to 8 Weeks)
|
Baseline to Study Completion (Up to 8 Weeks)
|
|
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3945262
大体时间:Baseline to Study Completion (Up to 8 weeks)
|
Baseline to Study Completion (Up to 8 weeks)
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.